In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews, September 2015

Executive Summary

This Month's Profile Group, Parkinson’s Disease: Start-Ups Seek Breakthroughs And Money, features profiles of MentiNova, Parkure and Prexton Therapeutics. Plus these Start-Ups Across Health Care: Apifix, Monopar Therapeutics, MitoGenetics, Preora Diagnostics, and Viking Therapeutics.

You may also be interested in...

ApiFix Ltd.

ApiFix Ltd. says its minimally invasive, fusionless technique for treating adolescent idiopathic scoliosis effectively remedies three hotly contested areas in spine: motion preservation, minimally invasive techniques and deformity correction. The device consists of an implantable ratcheting rod that only increases in length over a short segment of the spine, at the apex of the scoliotic curve, compared to a long segment) required for fusion surgery, and it requires only two pedicle screws to anchor the rod.

Preora Diagnostics Inc.

Just as the PAP smear has drastically reduced the incidence and number of deaths from cervical cancer over the decades, Preora Diagnostics Inc. expects its low-cost test to be an effective prescreening tool for lung cancer, in the convenience of a primary-care setting. The start-up believes its test will be able to identify asymptomatic stage 1 and stage 2 cancers.

In Vivo's Deals Of The Month, February 2018

In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts